Merck & Co., Inc. (NYSE:MRK) Stake Boosted by TRUE Private Wealth Advisors

TRUE Private Wealth Advisors increased its stake in Merck & Co., Inc. (NYSE:MRK) by 10.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,135 shares of the company’s stock after purchasing an additional 1,498 shares during the quarter. TRUE Private Wealth Advisors’ holdings in Merck & Co., Inc. were worth $1,361,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gantzert Investment Co. LLC ADV acquired a new position in Merck & Co., Inc. during the 4th quarter valued at approximately $2,373,000. Buckingham Capital Management Inc. increased its stake in shares of Merck & Co., Inc. by 4.8% in the fourth quarter. Buckingham Capital Management Inc. now owns 69,479 shares of the company’s stock worth $5,309,000 after acquiring an additional 3,177 shares during the period. Nations Financial Group Inc. IA ADV increased its stake in shares of Merck & Co., Inc. by 3.5% in the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,318 shares of the company’s stock worth $1,018,000 after acquiring an additional 446 shares during the period. Mcmillion Capital Management Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $3,074,000. Finally, Corient Capital Partners LLC increased its stake in shares of Merck & Co., Inc. by 25.7% in the fourth quarter. Corient Capital Partners LLC now owns 27,769 shares of the company’s stock worth $2,122,000 after acquiring an additional 5,682 shares during the period. 75.34% of the stock is currently owned by hedge funds and other institutional investors.

NYSE MRK traded up $1.54 during mid-day trading on Friday, reaching $85.00. 295,358 shares of the stock were exchanged, compared to its average volume of 9,473,462. The business’s 50 day moving average is $83.36 and its 200-day moving average is $80.92. Merck & Co., Inc. has a 1 year low of $66.10 and a 1 year high of $87.07. The company has a market capitalization of $220.40 billion, a P/E ratio of 19.55, a P/E/G ratio of 1.75 and a beta of 0.56. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.92 and a current ratio of 1.21.



Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.14. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 43.34%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. During the same period in the prior year, the firm posted $1.06 earnings per share. The firm’s quarterly revenue was up 12.4% compared to the same quarter last year. Equities analysts predict that Merck & Co., Inc. will post 4.91 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Investors of record on Monday, September 16th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

MRK has been the topic of a number of research reports. Credit Suisse Group reiterated a “buy” rating and issued a $95.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Leerink Swann initiated coverage on shares of Merck & Co., Inc. in a research note on Thursday. They issued an “outperform” rating and a $103.00 price objective on the stock. Citigroup increased their price objective on shares of Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, June 21st. They noted that the move was a valuation call. UBS Group increased their price objective on shares of Merck & Co., Inc. from $87.00 to $88.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Finally, Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a research note on Friday. They issued an “outperform” rating and a $103.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average price target of $92.56.

In related news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction on Friday, August 9th. The shares were sold at an average price of $85.09, for a total transaction of $546,873.43. Following the sale, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert M. Davis sold 216,718 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $85.43, for a total transaction of $18,514,218.74. Following the sale, the chief financial officer now directly owns 354,378 shares in the company, valued at $30,274,512.54. The disclosure for this sale can be found here. Corporate insiders own 0.27% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: Marijuana Stocks

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.